Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses.
Buruli ulcer (BU), caused by Mycobacterium ulcerans, is currently treated with a daily combination of rifampin and either injectable streptomycin or oral clarithromycin. An intermittent oral regimen would facilitate treatment supervision. We first evaluated the bactericidal activity of newer antimic...
Main Authors: | Aurélie Chauffour, Jérôme Robert, Nicolas Veziris, Alexandra Aubry, Kevin Pethe, Vincent Jarlier |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-08-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | https://doi.org/10.1371/journal.pntd.0007857 |
Similar Items
-
Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.
by: Aurélie Chauffour, et al.
Published: (2016-10-01) -
Targeting the Mycobacterium ulcerans cytochrome bc 1 :aa 3 for the treatment of Buruli ulcer
by: Nicole Scherr, et al.
Published: (2018-12-01) -
Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis.
by: Nicolas Veziris, et al.
Published: (2011-03-01) -
Resistance of M. leprae to quinolones: a question of relativity?
by: Nicolas Veziris, et al.
Published: (2013-11-01) -
Mycobacterium ulcerans Disease, Peru
by: Humberto Guerra, et al.
Published: (2008-03-01)